KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Liabilities (2016 - 2025)

Travere Therapeutics' Other Non-Current Liabilities history spans 15 years, with the latest figure at $7.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 11.85% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $7.6 million, up 11.85%, while the annual FY2025 figure was $7.6 million, 11.85% up from the prior year.
  • Other Non-Current Liabilities reached $7.6 million in Q4 2025 per TVTX's latest filing, up from $5.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $68.9 million in Q3 2022 to a low of $5.9 million in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $26.8 million, with a median of $14.3 million recorded in 2021.
  • The largest YoY upside for Other Non-Current Liabilities was 599.64% in 2023 against a maximum downside of 87.84% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $12.3 million in 2021, then fell by 23.55% to $9.4 million in 2022, then rose by 9.96% to $10.3 million in 2023, then tumbled by 34.15% to $6.8 million in 2024, then rose by 11.85% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Other Non-Current Liabilities are $7.6 million (Q4 2025), $5.9 million (Q3 2025), and $7.9 million (Q2 2025).